| Drug General Information |
| Drug ID |
D0B3ZM
|
| Former ID |
DNC004804
|
| Drug Name |
6-Mercapto-hexanoic acid phenylamide
|
| Drug Type |
Small molecular drug
|
| Indication |
Discovery agent
|
Investigative |
[1]
|
|---|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C12H17NOS
|
| Canonical SMILES |
C1=CC=C(C=C1)NC(=O)CCCCCS
|
| InChI |
1S/C12H17NOS/c14-12(9-5-2-6-10-15)13-11-7-3-1-4-8-11/h1,3-4,7-8,15H,2,5-6,9-10H2,(H,13,14)
|
| InChIKey |
IFUHTURYMZWNNJ-UHFFFAOYSA-N
|
| PubChem Compound ID |
|
| Target and Pathway |
| Target(s) |
Histone Deacetylase 8 |
Target Info |
Inhibitor |
[1]
|
|---|
| Histone deacetylase 4 |
Target Info |
Inhibitor |
[1]
|
| Histone deacetylase 1 |
Target Info |
Inhibitor |
[1]
|
| Histone deacetylase 6 |
Target Info |
Inhibitor |
[1]
|
| Histone deacetylase |
Target Info |
Inhibitor |
[1]
|
| Histone deacetylase 2 |
Target Info |
Inhibitor |
[1]
|
| Histone Deacetylase 10 |
Target Info |
Inhibitor |
[1]
|
|
KEGG Pathway
|
Alcoholism
|
|
Viral carcinogenesishsa05034:Alcoholism
|
|
Epstein-Barr virus infection
|
|
Viral carcinogenesis
|
|
MicroRNAs in cancerhsa04110:Cell cycle
|
|
Notch signaling pathway
|
|
Thyroid hormone signaling pathway
|
|
Huntington's disease
|
|
Amphetamine addiction
|
|
Pathways in cancer
|
|
Transcriptional misregulation in cancer
|
|
MicroRNAs in cancer
|
|
Chronic myeloid leukemiahsa05034:Alcoholism
|
|
Viral carcinogenesishsa04110:Cell cycle
|
|
Chronic myeloid leukemia
|
|
NetPath Pathway
|
IL2 Signaling PathwayNetPath_11:TCR Signaling PathwayNetPath_11:TCR Signaling Pathway
|
|
PANTHER Pathway
|
Wnt signaling pathwayP00057:Wnt signaling pathway
|
|
p53 pathwayP00057:Wnt signaling pathway
|
|
Pathway Interaction Database
|
Signaling events mediated by HDAC Class Ihdac_classii_pathway:Signaling events mediated by HDAC Class II
|
|
Signaling events mediated by HDAC Class III
|
|
Signaling events mediated by HDAC Class I
|
|
Sumoylation by RanBP2 regulates transcriptional repression
|
|
Validated nuclear estrogen receptor alpha networksmad2_3nuclearpathway:Regulation of nuclear SMAD2/3 signaling
|
|
Notch signaling pathway
|
|
E2F transcription factor network
|
|
Presenilin action in Notch and Wnt signaling
|
|
Regulation of Telomerase
|
|
Glucocorticoid receptor regulatory network
|
|
Regulation of Androgen receptor activity
|
|
IL3-mediated signaling events
|
|
Validated nuclear estrogen receptor alpha network
|
|
Retinoic acid receptors-mediated signaling
|
|
Hedgehog signaling events mediated by Gli proteins
|
|
Regulation of nuclear beta catenin signaling and target gene transcription
|
|
Validated targets of C-MYC transcriptional repression
|
|
Regulation of retinoblastoma protein
|
|
Notch-mediated HES/HEY networkhdac_classii_pathway:Signaling events mediated by HDAC Class II
|
|
Signaling events mediated by HDAC Class Ismad2_3nuclearpathway:Regulation of nuclear SMAD2/3 signaling
|
|
Direct p53 effectors
|
|
Regulation of nuclear beta catenin signaling and target gene transcriptionhdac_classii_pathway:Signaling events mediated by HDAC Class II
|
|
Reactome
|
NOTCH1 Intracellular Domain Regulates Transcription
|
|
Constitutive Signaling by NOTCH1 PEST Domain Mutants
|
|
Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
|
|
HDACs deacetylate histonesR-HSA-2122947:NOTCH1 Intracellular Domain Regulates Transcription
|
|
Constitutive Signaling by NOTCH1 HD+PEST Domain MutantsR-HSA-1538133:G0 and Early G1
|
|
p75NTR negatively regulates cell cycle via SC1
|
|
Formation of the beta-catenin:TCF transactivating complex
|
|
SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription
|
|
HDACs deacetylate histones
|
|
Deactivation of the beta-catenin transactivating complex
|
|
NoRC negatively regulates rRNA expression
|
|
RNA Polymerase I Transcription Initiation
|
|
Factors involved in megakaryocyte development and platelet productionR-HSA-2122947:NOTCH1 Intracellular Domain Regulates Transcription
|
|
Assembly of the primary ciliumR-HSA-193670:p75NTR negatively regulates cell cycle via SC1
|
|
Factors involved in megakaryocyte development and platelet production
|
|
WikiPathways
|
Integrated Pancreatic Cancer Pathway
|
|
Neural Crest Differentiation
|
|
Cell CycleWP474:Endochondral Ossification
|
|
Cardiac Hypertrophic Response
|
|
miR-targeted genes in muscle cell - TarBase
|
|
miR-targeted genes in lymphocytes - TarBase
|
|
miR-targeted genes in epithelium - TarBase
|
|
TarBasePathway
|
|
Cell Cycle
|
|
MicroRNAs in cardiomyocyte hypertrophyWP706:SIDS Susceptibility Pathways
|
|
Notch Signaling Pathway
|
|
TGF beta Signaling Pathway
|
|
IL-6 signaling pathway
|
|
Apoptosis-related network due to altered Notch3 in ovarian cancer
|
|
Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer
|
|
Notch Signaling Pathway
|
|
Retinoblastoma (RB) in Cancer
|
|
TWEAK Signaling Pathway
|
|
Integrated Breast Cancer Pathway
|
|
Signalling by NGF
|
|
RNA Polymerase I, RNA Polymerase III, and Mitochondrial Transcription
|
|
Mitotic G1-G1/S phases
|
|
Factors involved in megakaryocyte development and platelet production
|
|
Androgen receptor signaling pathwayWP2858:Ectoderm Differentiation
|
|
Cell CycleWP61:Notch Signaling Pathway
|
| References |
| REF 1 | J Med Chem. 2005 Feb 24;48(4):1019-32.Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxamates. |
|---|
